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Abstract: Diabetes mellitus is characterized by chronic hyperglycemia caused by a deficiency in insulin action, insulin secretion or both. Type 1 diabetes is classified as the destruction of beta cells leading to a deficiency in insulin
production. Type1 diabetes accounts for 5-10% of patients with diabetes and most commonly is caused by the
autoimmune destruction of the beta cells in the pancreas. The adaptive immune system is composed of antigen
specific T and B lymphocytes which play a central role in protecting the human body from infectious pathogens but
occasionally autoreactive T and B cells can escape immune tolerance, become activated and induce autoimmune
diseases. Naïve T cells require two distinct signals one delivered via the antigen receptor and the second through
the costimulatory receptor CD28 that leads to the induction of IL-2 gene transcription. IL-2 is an important T cell
growth factor that can influence both immunity and tolerance. Given its pivotal role it is not surprising that the
immune system places strict regulation over Il2 gene transcription that is controlled by a number of E3 ubiquitin
ligases that modulate TCR and CD28 signaling. This review will examine how different E3 ligases function to control
T effector cell differentiation and how studies in gene knockout animal models has been crucial in understanding
how these proteins function in vivo to regulate immune tolerance in the peripheral circulation.
Keywords: T cells, anergy, Foxp 3, TCR signalling, ubiquitin ligases

Introduction
Diabetes mellitus is a significant problem
throughout the world that is caused by chronic
hyperglycaemia and without treatment can
lead to severe life threatening complications
caused by dysfunction and/or failure of various
organs including eye, kidney, nerves, heart and
blood vessels. Genetic and environmental factors contribute to the etiology of diabetes. Type
1 diabetes (T1D) accounts for 5-10% of patients
with diabetes and occurs most commonly in
childhood and adolescence [1]. The disease is
caused by the autoimmune destruction of the
beta cells within the islets of Langerhans in the
pancreas due to activation of islet reactive T
and B cells. Pancreatic beta cells are the sole
source of insulin production in the body and following injury the regenerative potential of the
beta cell is limited. This is because beta cells
are largely senescent due to the expression of
cell cycle inhibitors such as p27kip1 and p16Ink4a

[2-4]. Also recent studies have identified that
there is no contribution to the adult beta cell
mass by specialized progenitors or stem cells
[5]. Instead adult beta cells are the product of
self-duplication [5, 6]. Therefore the partial
growth ability of the beta cell is insufficient to
permit recovery from cell loss as experienced in
overt T1D. As a result the loss of beta cell mass
leads to a chronic loss of insulin production and
dysregulation of blood glucose homeostasis
that eventually leads to the clinical symptoms
of diabetes.
Patients with T1D can secrete anti-insulin antibodies due to activation of autoreactive B cells,
while islet reactive CD4+ and CD8+ T cells have
been identified in the peripheral blood of
patients. The main target antigens of diabetogenic T cells include islet derived proteins such
as insulin, GAD65 and insulinoma associated
protein A2 (IA2) [7]. The activation of both T and
B lymphocytes in T1D patients indicates that
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the disease is caused by a generalized breakdown of immune tolerance whereby activation
of islet reactive CD4+ T cells can lead to cognate activation of islet specific B cells and the
generation of autoantibodies directed to islet
specific proteins. Animal models have been
particularly useful in helping to define the cellular and molecular basis of disease pathology
associated with T1D and these have contributed to a better understanding of the disease in
humans [8].
Immune tolerance to self antigens is established through central or peripheral mechanisms. Central tolerance occurs during T cell
development in the thymus through deletion of
self reactive T cells that express a TCR with
high affinity for self antigens. This process is
directed by the presentation of antigen by medullary epithelial cells that express the autoimmune regulator gene (AIRE) that directs ectopic
expression of tissue specific antigens in the
thymus [9-11]. In the absence of Aire central
tolerance is severely compromised and autoreactive T cells can escape deletion and enter the
periphery. Patients with the rare autoimmune
polyendocrinopathy syndrome 1 (APS-1) have
mutations in the Aire gene that predisposes to
organ specific autoimmunity including thyroiditis and diabetes [12, 13]. The efficiency of
clonal deletion is not absolute and so even in
healthy individuals a small proportion of autoreactive T cells can escape thymic deletion and
enter the peripheral circulation. The immune
system must control the activation of these
cells to prevent autoimmunity and this is
achieved through a combination of dominant
(extrinsic) and recessive (cell intrinsic)
mechanisms.
Dominant tolerance is mediated primarily by
the suppressive effects of regulatory T cells in
particular the naturally occurring CD4+ Foxp3+
Treg (nTregs) cells that arise during T cell development in the thymus or by inducible Tregs
(iTregs) that arise in the peripheral circulation in
response to tolerance inducing regimes (e.g.
mucosal delivery of antigen) [14, 15]. Recessive
tolerance is regulated by cell intrinsic mechanisms that control the fate of autoreactive T
cells especially in the periphery. The CD95
(Fas)/ CD95L (FasL) pathway is a member of
the TNF receptor family and plays a critical role
in regulating programmed cell death of activated T cells [16]. Other inhibitory pathways
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include PD-1/PD-1L and CTLA-4 which are
important for preventing cellular activation and
proliferation [17, 18]. Growth factors such as
interleukin 2 (IL-2) and transforming growth
factor–β (TGF-β) have important roles in regulating T cell proliferation and for maintaining
homeostasis of Treg cells in the peripheral circulation [19-21]. Self reactive T cells can undergo functional inactivation through a process
referred to as clonal anergy. The development
of anergy leads to an abortive activation that
makes cells unresponsive to stimulation
through the TCR [22, 23]. Several E3 ubiquitin
ligases are induced in anergic T cells and they
play a central role in ubiquitinating specific signalling molecules located downstream of the
TCR to target them for degradation.
In this chapter some of the key E3 ligases that
have specific roles in regulating T cell responses will be examined and how defects in the
function of these ligases can lead to organ specific autoimmune diseases.
E3 ubiquitin ligases
Ubiquitin is a 76 amino acid polypeptide that is
involved in the posttranslational modification
of proteins [24]. Ubiquitin is added by the
sequential activity of three enzymes; E1 is an
activating enzyme, E2 is a conjugating enzyme
and E3 is a ligase that attaches the ubiquitin
moiety to the target protein. Proteins can either
be subject to mono- or poly-ubiquitination [25,
26]. Ubiquitin molecules are generally linked
through the lysine (Lys) residue at position 48
or 63 and a protein can be tagged with a single
ubiquitin (i.e. monoubiquitinated) or it may be
tagged with multiple ubiquitins in an elongated
chain which is referred to as (polyubiquitination) [27, 28]. Proteins that become tagged with
multiple ubiquitins on Lys48 are destined for
degradation in the 26S proteosomal complex.
In contrast proteins that are monoubiquitinated
or have the addition of multiubiquitins to lysine
residues apart from Lys48 can alter protein
trafficking between subcellular compartments
or protein function [29].
Three families of E3 ligases have been identified including the really interesting new gene
(RING) type, homologous to the E6 associated
protein carboxy terminus (HECT) type and the
U-box type proteins [24]. The E3 ligases are
involved in the transfer of the ubiquitin from an
Am J Clin Exp Immunol 2012;1(2):101-112
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Figure 1. Induction of ubiquitin ligases in response to T cell anergy. A: T cells become fully activated in response to
signals through the TCR and CD28 costimulatory receptor. Intracellular signals are transduced from the TCR and
CD28 to the nucleus leading to IL-2 gene transcription and the secretion of the cytokine promoting autocrine and
paracrine growth of T cells, but ubiquitin ligase gene expression is inhibited. B: T cells that receive a signal only
through the TCR or experience sustained elevated levels of Cai++ leads to abortive activation and the development
of T cell anergy. The anergic state is characterized by inhibition of IL-2 gene transcription but increased expression
of a range of ubiquitin ligase genes.

appropriate E2 ubiquitin donor to the protein
substrate. Several RING and HECT type E3
ligases have been implicated in the regulation
of immune function and disrupting their function in vivo can have important consequences
on the development of autoimmune diseases
[30]. This outcome highlights that the immune
system relies on the E3 ligases to restrain the
autoimmune potential of self-reactive lymphocytes. In the following discussion we will focus
on the role of key E3 ligases such as Cbl-b, Itch,
Grail and Roquin to illustrate how these molecules control T cell activation.

the promoter of the Il2 gene locus that lead to
the de-repression of the Il2 gene, Il2 mRNA
transcripts become stabilized and are translated into protein to drive T cell proliferation [31]
(Figure 1A). IL-2 can act in an autocrine and
paracrine fashion to drive T cell proliferation
and to enable effector cell differentiation.
Therefore it is not surprising that the immune
system places the regulation of Il2 gene transcription under tight transcriptional control to
prevent inappropriate activation of naïve T cells
in the periphery and the possibility of
autoimmunity.

To achieve complete activation of naïve T cells
requires the delivery of two discrete signals,
one transmitted through the TCR and the other
which is delivered via the costimulatory receptor CD28 in response to binding to its ligands
CD80/CD86 on the surface of APCs. Both signals facilitate the recruitment of a number of
transcription factors (e.g. NF-kB, AP-1, NFAT) to

Naive T cells that receive only a TCR signal
undergo an abortive activation that leads to a
state of immune unresponsiveness termed
clonal anergy. Clonal anergy was originally
defined using mouse CD4+ Th cell clones stimulated in the absence of CD28 costimulation
and human CD4+ T cell clones can also be rendered anergic following stimulation with pep-
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tide antigen in the absence of APCs [32-34]. To
study the molecular and biochemical basis of T
cell anergy Rao and colleagues cultured T cells
in the presence of ionomycin to artificially raise
intracellular calcium levels and this was sufficient to induce a state of anergy [35, 36]. These
studies revealed that the induction of anergy in
T cells was an active process that is dependent
on new protein synthesis and is associated
with the increased expression of a range of E3
ubiquitin ligases such as Cbl-b, Itch, Grail and
Nedd4 and other negative regulators of TCR
signaling including diacyglycerol kinase, caspase3, Traf6, Ikaros, Egr2, Egr3 and CREM
(cyclic AMP response element modulator) [3743] (Figure 1B).
Casitas B-lineage lymphoma (Cbl) proteins
The Casitas B-lineage lymphoma (Cbl) family of
RING type ubiquitin ligases are key negative
regulators of cell surface growth factor receptor signals [44, 45]. Mammals have three Cbl
homologues c-Cbl, Cbl-b and Cbl-3 while D-Cbl
and Sli-1 are the Drosophila melanogaster and
Caenorhabditis elgans homologous proteins
respectively [46]. Cbl-3 does not appear to
have any role in the immune system but c-Cbl
and Cbl-b are required to modulate TCR signalling. C-cbl is predominantly expressed in the
thymus and testes [47] while Cbl-b proteins are
expressed primarily in peripheral T cells [48]. In
T cells c-Cbl functions to regulate the threshold
of TCR signalling by forming a complex with
Zap70 and CD3ζ to promotes CD3ζ ubiquitination. This leads to down regulation of the TCR/
CD3 complex following ligand binding to peptide/MHC complexes. In the absence of c-Cbl
thymocytes display high level expression of the
TCR/CD3 complex at the cell surface that
appears from the DP stage of development.
Negative selection of autoreactive thymocytes
proceeds normally in the thymus of c-Cbl-/- mice
but positive selection of thymocytes is
enhanced [49, 50]. There is no evidence of
spontaneous autoimmunity in c-Cbl-/- mice consistent with the intact negative selection and
normal Treg cell differentiation [49, 50] Ho,
Hoyne unpublished observations).
The Cbl-b protein is dispensable for T cell development but it does play important roles in TCR
modulation and the induction and maintenance
of T cell clonal anergy. Studies by Naramura et
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al showed the combined loss of c-Cbl and Cbl-b
leads to constitutive expression of TCR/CD3 at
high levels on thymocytes and these cells are
resistant to CD3 induced TCR modulation [48].
Cbl-b can interact with CrkL adapter protein
and C3G the guanine nucleotide exchange factor for Rap1 [51]. The loss of Cbl-b does not
affect the stability of CrkL but its association
with C3G that can lead to enhanced expression
of LFA-1 and clustering of T cells following TCR
signalling [51]. These results imply that Cbl-b is
a negative regulator of CrkL-C3G signaling. In
addition Cbl-b plays a crucial role as a negative
regulator of CD28 signaling in T cells to vav and
Rac1 [52] (Figure 2). Target proteins of Cbl-b
mediated ubiquitination include the p85 subunit of phosphatidyl inositol kinase (PI3K)
which is activated in response to CD28 signalling [53, 54] and is also required to inhibit phosphorylation of PLC-γ1 [55]. As Cblb deficient
mice are unable to restrain TCR signaling they
become highly susceptible to develop spontaneous autoimmunity and T cells display hyperproliferation in response to TCR signaling and
secrete IL-2 in the absence of a costimulatory
signal [48, 52, 56]. However, a recent report by
St Rose et al showed that Cblb deficient T cells
were still resistant to anergy induction when
adoptively transferred to recipient mice
expressing a neo-self target antigen expressed
either in soluble form or on mesenchymal tissues [57].
Additional evidence for the crucial role Cbl-b
plays in the regulation of immune tolerance
came with the identification of the Komeda diabetes prone (KDP) rat strain that develops
spontaneous type 1 diabetes due to a loss of
function mutation in Cblb [58]. The emergence
of autoimmune diabetes in the KDP strain
requires additional susceptibility factors including a diabetes-susceptible MHC haplotype that
leads to selection islet reactive T cells in the
thymus [58]. Studies with inbred strains of mice
indicate that Cbl-b on its own is not sufficient to
cause spontaneous autoimmunity. However,
diabetes can develop if the frequency of islet
reactive CD4+ T cells is elevated by transgenic
expression of a TCR specific for a neoself antigen expressed on islet beta cells. The TCR x
insHel model is a highly sensitized mouse strain
that has been used extensively to study defects
in negative selection and defective nTreg differentiation on the development of islet autoim-
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Figure 2. E3 ubiquitin ligases play a crucial role in regulating TCR signalling. The E3 ligases c-Cbl and Cbl-b can
ubiquitinate the TCR leading its internalization and targeting to endosome. The Cbl proteins also play an important
role in attenuating CrkL/C3G signalling. Cbl-b, Itch and Grail can also ubiquitinate intracellular signalling proteins
to dampen signalling into the nucleus. The ubiquitinated proteins are targeted to endosomes and these form lysosomes that result in the destruction of the proteins.

munity [11, 59-61]. The Cblb deficiency does
not affect negative selection of autoreactive T
cells in the TCR x insHel model, nor the differentiation of nTregs that develop in the thymus
but ~ 80% of Clbb -/- TCR x insHel double transgenic mice develop type 1 diabetes with extensive lymphocyte infiltration and immune mediated destruction of pancreatic beta cells [62].
However the studies identified a paradox
whereby the numbers of islet reactive T cells in
the peripheral circulation of Clbb -/- TCR x insHel
double transgenic mice were not dissimilar to
that of wild type TCR x insHel animals indicating
that the immune system was able to control the
homeostasis of naïve autoreactive T cells.
However the islet reactive T cells from Clbb -/TCR x insHel double transgenic mice proliferated extensively and secreted effector cytokines
following restimulation with HEL antigen in vitro
indicating a breakdown in T cell anergy compared to wild type cells from TCR x insHel which
remained unresponsive to the Hel stimulation.
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Grail and Itch and their role in T cell anergy
Grail is a RING type E3 ubiquitin ligase that controls autoimmunity in mice that is separate to
the function of Cbl-b described above. Grail is
encoded by the Rfn128 gene was originally
identified through a differential display PCR
screen of anergic CD4+ T cells. Its expression is
strongly induced following the induction of
anergy in CD4+ T cells and functions to inhibit
IL-2 production following TCR ligation [63]. Grail
controls TCR signalling in T cells by selectively
inhibiting RhoGTPase activity but it does not
affect Ras activation or MAPK signaling [64]
(Figure 2). Rfn128 deficient mice are more susceptible to autoimmune diseases and naïve T
cells from the gene knockout mice hyperproliferate in vitro following TCR stimulation in the
absence of costimulation which is similar to the
phenotype observed for Clbb -/- T cells [65]. Grail
also appears to have an important role in Treg
cell function as the increased susceptibility to

Am J Clin Exp Immunol 2012;1(2):101-112
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autoimmunity of Rfn128 deficient mice is due
to a lack of suppressive activity of Tregs [65].
The HECT (Homologous to the E6 associated
protein carboxy terminus) type E3 ubiquitin
ligases also play a role in the regulation of T cell
anergy [35, 66]. The Itchy mouse strain develops a spontaneous and lethal systemic proinflammatory disease consistent with a failure of
peripheral tolerance. The disease is associated
with an expansion of Th2 type T cells that trigger a chronic pulmonary interstitial inflammation with elevated levels of IgE antibodies that
results in skin irritation and the mice itch incessantly [53, 67]. A mutation in the Itch gene was
responsible for the disease manifestation in
these mice [67]. As an E3 ligase itch promotes
ubiquitination of target proteins including JunB,
Cbl-b, PKC-q and Bcl-10 [35, 53, 68]. It was
originally shown that Itch targets JunB for degradation which is a transcription factor required
for the formation of the AP1 transcription factor
that regulates Il-2 gene transcription. In
response to activation of calcium/calcineurin
signaling in T cells Itch targets the degradation
of both PLC-γ1 and PKC-θ to dampen TCR signalling because reduced levels of these two
proteins reduces the longevity of the immune
synapse formed between the T cell and APC
[35] (Figure 2).
Additional roles for Cbl-b and Itch in the control of inducible Treg cell function
Thymus derived CD4+ T regulatory cells or natural Tregs (nTreg cells) are essential for controlling autoimmune and inflammatory responses.
nTreg cells represent a specialized subpopulation of T cells that arise in the thymus during
CD4+ TCRaβ+ cell differentiation through
expression of the fork head winged helix transcription factor Foxp3 [15]. The expression of
Foxp3 leads to a program of gene expression
that directs to Treg differentiation and there is
a requirement for sustained Foxp3 expression
to maintain their immunoregulatory function in
the periphery [69-71]. The importance of CD4+
Foxp3+ Tregs in the maintenance of immune
tolerance is supported by the lethal multiorgan
autoimmunity that occurs in both humans and
mice due to a failure in Treg cell differentiation
[72, 73]. The selection of Treg cells in the thymus requires strong TCR: MHC interactions [74]
and co-stimulatory signals from CD28 [75-77].

106

Mature nTreg cells migrate from the thymus
and enter the peripheral T cell pool where their
homeostasis is controlled by distinct mechanisms compared to naive and memory T cells.
IL-2, a member of γc cytokine family, is critical
for the long term survival of Treg cells in the
periphery [78]. A second subset of cells with
immunosuppressive functions have been characterized. These are known as inducible Tregs
(iTregs) and are derived in the periphery from
naïve CD4+ CD25- T cells [79]. iTreg cells can
be readily isolated in vitro by culturing naïve
CD4+ T cells in the presence of TGF-β (and
IL-10, IL-2) and they begin to express Foxp3 and
they differentiate as a Treg cells [80-83] . The
iTregs function in an equivalent manner in
being able to suppress responses of other T
cells whether in vitro or in vivo. The mechanism
of suppression by Tregs is mediated by secretion of inhibitory cytokines (e.g. IL10, IL-35 or
TGF-β) and/or cell-cell contact [15].
Naïve CD4+ CD25- T cells from Cblb -/- and Itch/mice show poor induction of Foxp3 expression and the iTregs induced are functionally
less suppressive in co-culture experiments with
wild type naïve T cells [62, 66, 84, 85]. The
mechanism by which Cbl-b and Itch regulate
iTreg cell differentiation in response to TGF-b
stimulation is quite distinct. An important target of Itch in naïve CD4+T cells is the TGF-b
induced early gene (TIEG1, Klf10) product [85].
Studies by Liu and colleagues have revealed
that Itch and TIEG1 can bind to the promoter of
Foxp3 to allow transactivation [85]. When wild
type naïve CD4+ T cells are cultured in the presence of TGF-b T cell proliferation is inhibited
and Itch and TIEG1 lead to the induction of
Foxp3 directing iTreg cell differentiation. In the
absence of Itch, naïve CD4+ T cells are resistant to the inhibitory effects of TGF-β, and
TIEG1 is unable to promote efficient expression
of Foxp3 and preventing iTreg cell differentiation [85]. Similarly, CD4+ TIEG1-/- T cells are
resistant to the effects of TGF-b in vitro and are
unable to induce Foxp3 expression [85]. Taken
together these studies have identified an
important role between the E3 ubiquitin ligase
Itch and TIEG1 in the differentiation of iTreg
cells in vivo.
As discussed above, Cbl-b plays an important
role in modulating the strength of TCR signaling
in T cells. Signaling downstream of the TCR and
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Figure 3. Role of ubiquitin ligases in the induction of Foxp3 gene expression in iTreg cells. Naïve CD4+ T cells can
be induced to differentiate into iTreg cells through induction of the foxp3 gene expression. TGF-b signalling leads to
phosphorylation of SMAD2/3 which associates with SMAD4 and the complex translocates to the nucleus where it
leads to induction of the TIEG1 gene. The TIEG1 protein can be mono-ubiquitinated by the HECT ligase Itch which
promotes its migration to the nucleus where it can bind to the Foxp3 promoter in association with SMAD complex
leading to induction of Foxp3 expression. The expression of Foxp3 triggers the Treg differentiation program and
leads to control of immune responses. Cbl-b ubiquitinates PI3K targeting it for degradation and this prevents activation of the serine threonine kinase AKT which is required for phosphorylation of the Foxo transcription factors. In the
absence of phosphorylation the Foxo transcription factors translocate to the nucleus where they bind to the Foxp3
promoter to induce gene expression. B: In the absence of TGFbR signalling the Cbl-b ubiquitin ligase ubiquitinates
the SMAD2/3 complex which targets it for degradation and thus prevents Foxp3 expression.

growth factor receptors (e.g. IL-2R) leads to
activation of PI3 kinase (PI3K), the serine threonine kinase AKT and mammalian target of
rapamycin (mTOR) to stimulate proliferation
and to help activated T cells to avoid the induction of anergy [86, 87]. Activation of AKT
increases the activity of mTOR which in turn
phosphorylates the Foxo transcription factors
(e.g. Foxo 1 and Foxo 3a) which leads to their
nuclear export and subsequent degradation
[88]. The immunosuppressive drug Rapamycin
is an inhibitor of mTOR, and treatment of naïve
T cells with rapamycin can induce T cell anergy
in vitro [89]. The induction of anergy requires
the complete inhibition of mTOR activity and
there is heightened activation of the calcineurin/NFAT pathway [23]. It is now apparent that
the induction of Foxp3 expression in naïve T

107

cells to induce iTreg differentiation in response
to TGF-b treatment requires proteins that block
PI3K activity such as Cbl-b and PTEN [90, 91].
mTOR deficient CD4+ T cells are hypersensitive
to TGF-β treatment and switch on Foxp3. Two
recent studies have identified that regulation of
the Foxo1 and Foxo3a transcription factors is
essential for TGF-β mediated iTreg cell differentiation [84, 92, 93]. Cblb is required in anergic
CD4+T cells to inhibit PI3K signaling by targeting the p85 subunit for degradation [35, 55]. By
disrupting PI3K signaling, this prevents AKT
activation and the Foxo1 and Foxo3a transcription factors remain de-phosphorylated and can
induce expression of Foxp3 in response to
TGF-b signaling. However in the absence of Cblb, PI3K/AKT signaling in naïve T cells is not
inhibited, and Foxo1 and Foxo3a become phos-
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phorylated and are degraded and are not available to induce Foxp3 expression resulting in
impaired iTreg differentiation [84, 94] (Figure
3).
Roquin constrains autoimmunity by regulating
Tfh cell functions in vivo
Roquin is a relatively new member of the RING
finger protein family with E3 ligase activity that
is encoded by the Rc3h1 gene [61]. The Roquin
protein has emerged to be a key regulator of T
follicular helper (Tfh) cell differentiation in vivo.
Tfh cells are a relatively new Th cell subset that
plays a critical role in regulation of germinal
centre (GC) responses in the spleen and for
promoting B cell responses to antigen. The
induction of Tfh cells is dependent on Bcl6 and
the cytokine IL-21 [95-97]. Originally discovered through an ENU mutagenesis screen in
mice for autoimmune prone phenotypes, the
Sanroque mutation is a hypomorphic allele
caused by a point mutation in the conserved
Roq domain leading to loss of function of the
Roquin protein [61]. The Rch31san/san mice on a
C57BL/6 genetic background develop a systemic autoimmune Lupus-like disease that
results in spontaneous GC formation in the
spleen, increased numbers of Tfh cells, elevated levels of double stranded DNA antibodies
and serum immunoglobulins that leads to the
premature death of most Rch31san/san mice
[61]. CD4+ Tfh cells in Rch31san/san mice constitutively express high levels of inducible costimulator (ICOS) at the cell surface of T cells and
this phenotype is responsible for driving the
spontaneous GC formation in the spleen of
Sanroque mice [61]. Roquin plays a key role in
regulating the expression of Icos mRNA in T
cells by binding to the 3’ untranslated region
targeting it for degradation [98]. The loss of
function of Rc3h1 leads to increased stability
of Icos mRNA CD4+ Tfh cells express constitutively high levels of ICOS at the cell surface that
allows them to interact with autoreactive B
cells to promote autoimmune responses.

tion and proliferation of autoreactive T cell
clones. Thus the E3 ligases are not only play
key roles in attenuating TCR signaling, but they
appear to have evolved important roles in
directing iTreg cell differentiation as well. Thus
the breakdown in anergy can not only unleashes TCR signaling in autoreactive T cell clones,
but disables an immunoregulatory checkpoint
that is normally controlled by iTreg cells.
The development of autoimmune diabetes is
controlled by genetic and environmental factors that can lead to a breakdown in the immunoregulatory checkpoints that normally prevent
activation of autoreactive T cells. As highlighted
in this review there are multiple E3 ubiquitin
ligases that are used to control the fate of naïve
T cells. Some of these E3 ligases are crucial for
dampening TCR signaling, but as highlighted by
the function of Roquin, new mechanisms of
controlling the activation and/or differentiation
of autoreactive T cells could still emerge.
Roquin is one of the first E3 ligases to be
involved in controlling mRNA degradation of a
key protein involved in costimulation of naïve T
cells.
The diversity of E3 ligases involved in controlling autoimmunity to organ specific antigens
such as in type 1 diabetes makes these proteins potential targets for immune therapy. The
link between Cbl-b, Itch and iTreg cell differentiation is an exciting development. There is
great excitement as to the role of iTregs in
immune cell therapy for the treatment of autoimmune diseases. As we come to a clear understanding of how to induce Foxp3 expression to
direct iTreg cell differentiation, the use of Treg
therapy may continue to flourish and provide an
exciting opportunity to hopefully treat and cure
type 1 diabetes in the future.
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